UK markets close in 21 minutes

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
82.07-9.13 (-10.02%)
As of 11:09AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 17.31B
Enterprise value 17.33B
Trailing P/E 104.83
Forward P/E 34.01
PEG ratio (5-yr expected) 0.75
Price/sales (ttm)7.22
Price/book (mrq)3.50
Enterprise value/revenue 7.16
Enterprise value/EBITDA 55.96

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-1.35%
S&P500 52-week change 322.64%
52-week high 399.56
52-week low 376.02
50-day moving average 387.78
200-day moving average 389.10

Share statistics

Avg vol (3-month) 31.41M
Avg vol (10-day) 31.61M
Shares outstanding 5189.78M
Implied shares outstanding 6191.52M
Float 8188.32M
% held by insiders 10.84%
% held by institutions 1100.82%
Shares short (15 Apr 2024) 43.69M
Short ratio (15 Apr 2024) 42.76
Short % of float (15 Apr 2024) 41.96%
Short % of shares outstanding (15 Apr 2024) 41.94%
Shares short (prior month 15 Mar 2024) 42.96M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 8.31%
Operating margin (ttm)12.09%

Management effectiveness

Return on assets (ttm)1.77%
Return on equity (ttm)4.22%

Income statement

Revenue (ttm)2.47B
Revenue per share (ttm)13.12
Quarterly revenue growth (yoy)8.80%
Gross profit (ttm)N/A
EBITDA 293.47M
Net income avi to common (ttm)205.46M
Diluted EPS (ttm)0.87
Quarterly earnings growth (yoy)74.40%

Balance sheet

Total cash (mrq)1.05B
Total cash per share (mrq)5.51
Total debt (mrq)1.09B
Total debt/equity (mrq)21.44%
Current ratio (mrq)2.74
Book value per share (mrq)26.74

Cash flow statement

Operating cash flow (ttm)280.16M
Levered free cash flow (ttm)68.47M